Apolipoproteins have a major role in cellular tumor dormancy in triple negative breast cancer: In-silico study.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
04 Oct 2024
04 Oct 2024
Historique:
received:
03
06
2024
accepted:
28
08
2024
medline:
5
10
2024
pubmed:
5
10
2024
entrez:
4
10
2024
Statut:
epublish
Résumé
Triple-negative breast cancer (TNBC) lacks estrogen, progesterone, and human epidermal growth factor receptors and has a poor prognosis as it is resistant to chemotherapy. A new treatment option for this type of cancer may be by putting these malignant cells into dormancy. The oocyte's embryonic milieu presents a unique tumor reversion microenvironment by inducing growth arrest and changing cells' phenotypes. We conducted an in-silico study to determine the most likely oocyte extract (OE) proteins involved in inducing dormancy using HDock, CluPro, and molecular dynamic (MD) simulation. Results showed low energy scores for complexes between OE proteins and four surface markers: K1C14, CLD3, CLD4, and ITA6. Apolipoprotein A1 (APOA1) and Apolipoprotein C3 (APOC3) showed the highest stability and affinity with these four surface markers: K1C14, CLD3, CLD4, and ITA6. These proteins are involved in key tumor-related pathways such as angiogenesis, proliferation, apoptosis, and migration. This will pave the way for exploring novel therapeutic options to induce dormancy in TNBC cells.
Identifiants
pubmed: 39367005
doi: 10.1038/s41598-024-71522-z
pii: 10.1038/s41598-024-71522-z
doi:
Substances chimiques
Apolipoproteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
23146Informations de copyright
© 2024. The Author(s).
Références
Breast cancer, https://www.who.int/news-room/fact-sheets/detail/breast-cancer
Lim, B. et al. Current treatment of early breast cancer: Adjuvant and neoadjuvant therapy. F1000Res https://doi.org/10.12688/F1000RESEARCH.4340.1 (2014).
doi: 10.12688/F1000RESEARCH.4340.1
pubmed: 25685326
pmcid: 4314662
Song, W. M. et al. Pseudo-temporal dynamics of chemoresistant triple negative breast cancer cells reveal EGFR/HER2 inhibition as synthetic lethal during mid-neoadjuvant chemotherapy. iScience 26, 106064. https://doi.org/10.1016/J.ISCI.2023.106064 (2023).
doi: 10.1016/J.ISCI.2023.106064
pubmed: 36824282
pmcid: 9942122
Newton, E. E., Mueller, L. E., Treadwell, S. M., Morris, C. A. & Machado, H. L. Molecular targets of triple-negative breast cancer: Where do we stand?. Cancers (Basel) https://doi.org/10.3390/CANCERS14030482/S1 (2022).
doi: 10.3390/CANCERS14030482/S1
pubmed: 36230490
Bisht, S. et al. Cancer stem cells: From an insight into the basics to recent advances and therapeutic targeting. Stem Cells Int. https://doi.org/10.1155/2022/9653244 (2022).
doi: 10.1155/2022/9653244
pubmed: 35800881
pmcid: 9256444
Recasens, A. & Munoz, L. Targeting cancer cell dormancy. Trends Pharmacol. Sci. 40(2), 128–41 (2019).
doi: 10.1016/j.tips.2018.12.004
pubmed: 30612715
Min, H. Y. & Lee, H. Y. Cellular dormancy in cancer: Mechanisms and potential targeting strategies. Cancer Res. Treat. Off. J. Korean Cancer Assoc. 55, 720. https://doi.org/10.4143/CRT.2023.468 (2023).
doi: 10.4143/CRT.2023.468
Pensotti, A., Bizzarri, M. & Bertolaso, M. The phenotypic reversion of cancer: Experimental evidences on cancer reversibility through epigenetic mechanisms (Review). Oncol. Rep. https://doi.org/10.3892/OR.2024.8707 (2024).
doi: 10.3892/OR.2024.8707
pubmed: 38275101
pmcid: 10835663
Allegrucci, C. et al. Epigenetic reprogramming of breast cancer cells with oocyte extracts. Mol. Cancer. 10, 1–14. https://doi.org/10.1186/1476-4598-10-7/FIGURES/6 (2011).
doi: 10.1186/1476-4598-10-7/FIGURES/6
El-Gammal, Z., AlOkda, A. & El-Badri, N. Role of human oocyte-enriched factors in somatic cell reprograming. Mech. Ageing Dev. 175, 88–99. https://doi.org/10.1016/J.MAD.2018.05.009 (2018).
doi: 10.1016/J.MAD.2018.05.009
pubmed: 29890177
Saad, N. et al. Cancer reversion with oocyte extracts is mediated by cell cycle arrest and induction of tumour dormancy. Oncotarget 9, 16008–16027. https://doi.org/10.18632/ONCOTARGET.24664 (2018).
doi: 10.18632/ONCOTARGET.24664
pubmed: 29662623
pmcid: 5882314
He, Y., Chen, J., Ma, Y. & Chen, H. Apolipoproteins: New players in cancers. Front. Pharmacol. 13, 1051280. https://doi.org/10.3389/FPHAR.2022.1051280/BIBTEX (2022).
doi: 10.3389/FPHAR.2022.1051280/BIBTEX
pubmed: 36506554
pmcid: 9732396
Malla, M. A. et al. Emerging frontiers in microbe-mediated pesticide remediation: Unveiling role of omics and In silico approaches in engineered environment. Environ. Pollut. 299, 118851. https://doi.org/10.1016/J.ENVPOL.2022.118851 (2022).
doi: 10.1016/J.ENVPOL.2022.118851
pubmed: 35085655
El-Gammal, Z. et al. Human-stimulated oocyte extract induces genetic and mitochondrial reprogramming of mesenchymal stromal cells. PLoS One 15, e0232759. https://doi.org/10.1371/JOURNAL.PONE.0232759 (2020).
doi: 10.1371/JOURNAL.PONE.0232759
pubmed: 32453737
pmcid: 7250418
Mitchell, C. MultAlin–multiple sequence alignment. Bioinformatics 9, 614–614. https://doi.org/10.1093/BIOINFORMATICS/9.5.614 (1993).
doi: 10.1093/BIOINFORMATICS/9.5.614
von Mering, C. et al. STRING: A database of predicted functional associations between proteins. Nucleic Acids Res. 31, 258–261. https://doi.org/10.1093/NAR/GKG034 (2003).
doi: 10.1093/NAR/GKG034
PyMOL | pymol.org, https://pymol.org/2/
Volkamer, A., Kuhn, D., Grombacher, T., Rippmann, F. & Rarey, M. Combining global and local measures for structure-based druggability predictions. J. Chem. Inf. Model 52, 360–372. https://doi.org/10.1021/CI200454V/ASSET/IMAGES/MEDIUM/CI-2011-00454V_0015.GIF (2012).
doi: 10.1021/CI200454V/ASSET/IMAGES/MEDIUM/CI-2011-00454V_0015.GIF
pubmed: 22148551
Volkamer, A., Griewel, A., Grombacher, T. & Rarey, M. Analyzing the topology of active sites: On the prediction of pockets and subpockets. J. Chem. Inf. Model 50, 2041–2052. https://doi.org/10.1021/CI100241Y/ASSET/IMAGES/MEDIUM/CI-2010-00241Y_0012.GIF (2010).
doi: 10.1021/CI100241Y/ASSET/IMAGES/MEDIUM/CI-2010-00241Y_0012.GIF
pubmed: 20945875
Kozakov, D. et al. The ClusPro web server for protein–protein docking. Nat. Protoc. 2017(12), 255–278. https://doi.org/10.1038/nprot.2016.169 (2017).
doi: 10.1038/nprot.2016.169
Yan, Y., Zhang, D., Zhou, P., Li, B. & Huang, S. Y. HDOCK: A web server for protein–protein and protein–DNA/RNA docking based on a hybrid strategy. Nucl. Acids Res. 45, W365–W373. https://doi.org/10.1093/NAR/GKX407 (2017).
doi: 10.1093/NAR/GKX407
pubmed: 28521030
pmcid: 5793843
Laskowski, R. A. & Swindells, M. B. LigPlot+: Multiple ligand-protein interaction diagrams for drug discovery. J. Chem. Inf. Model 51, 2778–2786. https://doi.org/10.1021/CI200227U/ASSET/IMAGES/MEDIUM/CI-2011-00227U_0006.GIF (2011).
doi: 10.1021/CI200227U/ASSET/IMAGES/MEDIUM/CI-2011-00227U_0006.GIF
pubmed: 21919503
Pettersen, E. F. et al. UCSF Chimera—A visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612. https://doi.org/10.1002/JCC.20084 (2004).
doi: 10.1002/JCC.20084
pubmed: 15264254
Tze Lin, K. et al. Interaction of the nanobio-based reagent with sodium fluorescein and lipids via bioinformatics for forensic fingerprint visualisations. J. Biomol. Struct. Dyn. 41, 15045–15052. https://doi.org/10.1080/07391102.2023.2186709 (2023).
doi: 10.1080/07391102.2023.2186709
pubmed: 36880661
Van Der Spoel, D. et al. GROMACS: Fast, flexible, and free. J. Comput. Chem. 26, 1701–1718. https://doi.org/10.1002/JCC.20291 (2005).
doi: 10.1002/JCC.20291
pubmed: 16211538
Wang, D. W., Zhang, W. H., Danil, G., Yang, K. & Hu, J. K. The role and mechanism of claudins in cancer. Front. Oncol. https://doi.org/10.3389/FONC.2022.1051497 (2022).
doi: 10.3389/FONC.2022.1051497
pubmed: 37078004
pmcid: 9837830
Levine, F. & Ogunwobi, O. O. Targeting PVT1 Exon 9 re-expresses claudin 4 protein and inhibits migration by Claudin—Low triple negative breast cancer cells. Cancers (Basel) 13, 1–14. https://doi.org/10.3390/CANCERS13051046 (2021).
doi: 10.3390/CANCERS13051046
Ji, H. et al. Visualizing cytokeratin-14 levels in basal-like breast cancer via ImmunoSPECT imaging. Mol. Pharm. 19, 3542–3550. https://doi.org/10.1021/ACS.MOLPHARMACEUT.2C00004/SUPPL_FILE/MP2C00004_SI_001.PDF (2022).
doi: 10.1021/ACS.MOLPHARMACEUT.2C00004/SUPPL_FILE/MP2C00004_SI_001.PDF
pubmed: 35285645
Mrouj, K. et al. Ki-67 regulates global gene expression and promotes sequential stages of carcinogenesis. Proc Natl Acad Sci U S A. 118, e2026507118. https://doi.org/10.1073/PNAS.2026507118/SUPPL_FILE/PNAS.2026507118.SD05.PDF (2021).
doi: 10.1073/PNAS.2026507118/SUPPL_FILE/PNAS.2026507118.SD05.PDF
pubmed: 33658388
pmcid: 7958263
Taschauer, A. et al. Peptide-targeted polyplexes for aerosol-mediated gene delivery to CD49f-overexpressing tumor lesions in lung. Mol. Ther. Nucl. Acids 18, 774–786. https://doi.org/10.1016/j.omtn.2019.10.009 (2019).
doi: 10.1016/j.omtn.2019.10.009
Ben Hassen, C. et al. Apolipoprotein-mediated regulation of lipid metabolism induces distinctive effects in different types of breast cancer cells. Breast Cancer Res. 22, 1–17. https://doi.org/10.1186/S13058-020-01276-9 (2020).
doi: 10.1186/S13058-020-01276-9
Wang, Y. et al. Stromal clusterin expression predicts therapeutic response to neoadjuvant chemotherapy in triple negative breast cancer. Clin. Breast Cancer 18, e373–e379. https://doi.org/10.1016/J.CLBC.2017.08.007 (2018).
doi: 10.1016/J.CLBC.2017.08.007
pubmed: 28890185
UniProt, https://www.uniprot.org/
O’Connor, M. N. et al. LRG1 destabilizes tumor vessels and restricts immunotherapeutic potency. Med (N Y) 2, 1231-1252.e10. https://doi.org/10.1016/J.MEDJ.2021.10.002 (2021).
doi: 10.1016/J.MEDJ.2021.10.002
Buoso, E. et al. Cortisol-induced SRSF3 expression promotes GR splicing, RACK1 expression and breast cancer cells migration. Pharmacol. Res. 143, 17–26. https://doi.org/10.1016/J.PHRS.2019.03.008 (2019).
doi: 10.1016/J.PHRS.2019.03.008
pubmed: 30862604
Fu, Y., Du, Q., Cui, T., Lu, Y. & Niu, G. A pan-cancer analysis reveals role of clusterin (CLU) in carcinogenesis and prognosis of human tumors. Front. Genet. 13, 1056184. https://doi.org/10.3389/FGENE.2022.1056184/BIBTEX (2023).
doi: 10.3389/FGENE.2022.1056184/BIBTEX
pubmed: 36685863
pmcid: 9846084
Becherini, P. et al. SIRT6 enhances oxidative phosphorylation in breast cancer and promotes mammary tumorigenesis in mice. Cancer Metab. 2021(9), 1–16. https://doi.org/10.1186/S40170-021-00240-1 (2021).
doi: 10.1186/S40170-021-00240-1
Yang, Y. et al. The NQO1/PKLR axis promotes lymph node metastasis and breast cancer progression by modulating glycolytic reprogramming. Cancer Lett. 453, 170–183. https://doi.org/10.1016/J.CANLET.2019.03.054 (2019).
doi: 10.1016/J.CANLET.2019.03.054
pubmed: 30954648
Pradubyat, N., Sakunrangsit, N., Mutirangura, A. & Ketchart, W. NADPH: Quinone oxidoreductase 1 (NQO1) mediated anti-cancer effects of plumbagin in endocrine resistant MCF7 breast cancer cells. Phytomedicine 66, 153133. https://doi.org/10.1016/J.PHYMED.2019.153133 (2020).
doi: 10.1016/J.PHYMED.2019.153133
pubmed: 31790893
Mondal, M., Conole, D., Nautiyal, J. & Tate, E. W. UCHL1 as a novel target in breast cancer: Emerging insights from cell and chemical biology. Br. J. Cancer 126, 24. https://doi.org/10.1038/S41416-021-01516-5 (2022).
doi: 10.1038/S41416-021-01516-5
pubmed: 34497382
Jemmerson, R., Staskus, K., Higgins, L. A., Conklin, K. & Kelekar, A. Intracellular leucine-rich alpha-2-glycoprotein-1 competes with Apaf-1 for binding cytochrome c in protecting MCF-7 breast cancer cells from apoptosis. Apoptosis 26, 71–82. https://doi.org/10.1007/S10495-020-01647-9 (2021).
doi: 10.1007/S10495-020-01647-9
pubmed: 33386492
pmcid: 7904597
Pereyra, C. E., Dantas, R. F., Ferreira, S. B., Gomes, L. P. & Silva, F. P. The diverse mechanisms and anticancer potential of naphthoquinones. Cancer Cell Int. 2019(19), 1–20. https://doi.org/10.1186/S12935-019-0925-8 (2019).
doi: 10.1186/S12935-019-0925-8
Li, J., He, D., Li, S., Xiao, J. & Zhu, Z. Ferroptosis: The emerging player in remodeling triple-negative breast cancer. Front. Immunol. 14, 1284057. https://doi.org/10.3389/FIMMU.2023.1284057/BIBTEX (2023).
doi: 10.3389/FIMMU.2023.1284057/BIBTEX
pubmed: 37928550
pmcid: 10623117
Koltai, T. Clusterin: A key player in cancer chemoresistance and its inhibition. Onco. Targets Ther. 7, 447. https://doi.org/10.2147/OTT.S58622 (2014).
doi: 10.2147/OTT.S58622
pubmed: 24672247
pmcid: 3964162
Ross, D. & Siegel, D. Functions of NQO1 in cellular protection and CoQ10 metabolism and its potential role as a redox sensitive molecular switch. Front. Physiol. https://doi.org/10.3389/FPHYS.2017.00595 (2017).
doi: 10.3389/FPHYS.2017.00595
pubmed: 29109686
pmcid: 5660098
Cordeiro, Y. G. et al. Proteomic analysis identifies FNDC1, A1BG, and antigen processing proteins associated with tumor heterogeneity and malignancy in a canine model of breast cancer. Cancers (Basel) https://doi.org/10.3390/CANCERS13235901 (2021).
doi: 10.3390/CANCERS13235901
pubmed: 34885011
Zhao, Y. et al. Ang II-AT1R increases cell migration through PI3K/AKT and NF-κB pathways in breast cancer. J. Cell Physiol. 229, 1855–1862. https://doi.org/10.1002/JCP.24639 (2014).
doi: 10.1002/JCP.24639
pubmed: 24692224
Liu, S. et al. Deubiquitinase activity profiling identifies UCHL1 as a candidate oncoprotein that promotes TGFβ-induced breast cancer metastasis. Clin. Cancer Res. 26, 1460–1473. https://doi.org/10.1158/1078-0432.CCR-19-1373/75345/AM/DEUBIQUITINASE-ACTIVITY-PROFILING-IDENTIFIES-UCHL1 (2020).
doi: 10.1158/1078-0432.CCR-19-1373/75345/AM/DEUBIQUITINASE-ACTIVITY-PROFILING-IDENTIFIES-UCHL1
pubmed: 31857432
Lin, M. et al. The role of leucine-rich alpha-2-glycoprotein-1 in proliferation, migration, and invasion of tumors. J. Cancer Res. Clin. Oncol. 148, 283–291. https://doi.org/10.1007/S00432-021-03876-0 (2022).
doi: 10.1007/S00432-021-03876-0
pubmed: 35037101
Hong, O. Y. et al. Inhibition of cell invasion and migration by targeting matrix metalloproteinase-9 expression via sirtuin 6 silencing in human breast cancer cells. Sci. Rep. 12, 12125. https://doi.org/10.1038/S41598-022-16405-X (2022).
doi: 10.1038/S41598-022-16405-X
pubmed: 35840633
pmcid: 9287314
Chen, F. et al. Ceruloplasmin correlates with immune infiltration and serves as a prognostic biomarker in breast cancer. Aging (Albany NY) 13, 20438. https://doi.org/10.18632/AGING.203427 (2021).
doi: 10.18632/AGING.203427
pubmed: 34413268
Ramchandani, D. et al. Copper depletion modulates mitochondrial oxidative phosphorylation to impair triple negative breast cancer metastasis. Nat. Commun. 2021(12), 1–16. https://doi.org/10.1038/s41467-021-27559-z (2021).
doi: 10.1038/s41467-021-27559-z
Cai, B., Fan, J., Zeng, M., Zhang, L. & Fu, B. M. Adhesion of malignant mammary tumor cells MDA-MB-231 to microvessel wall increases microvascular permeability via degradation of endothelial surface glycocalyx. J. Appl. Physiol. 113, 1141–1153. https://doi.org/10.1152/JAPPLPHYSIOL.00479.2012/ASSET/IMAGES/LARGE/ZDG0191203050009.JPEG (2012).
doi: 10.1152/JAPPLPHYSIOL.00479.2012/ASSET/IMAGES/LARGE/ZDG0191203050009.JPEG
pubmed: 22858626
pmcid: 3487494
Karamanou, K. et al. Evaluation of lumican effects on morphology of invading breast cancer cells, expression of integrins and downstream signaling. FEBS J. 287, 4862–4880. https://doi.org/10.1111/FEBS.15289 (2020).
doi: 10.1111/FEBS.15289
pubmed: 32160387